Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL) -- Ignore unavailable to you. Want to Upgrade?

To: mcbio who wrote (410)	1/13/2009 3:23:44 PM
From: tuck	Read Replies (2) \| Respond to of 566

Howdy, mcbio, R788 is the oral solid reformulation of R406. I haven't seen the paper, cuz it's not cheap, but I'd guess both were tested in this way, and that's why both show up in the abstract. The FDA already has this data. Such tox studies are mandatory before further human trials are permitted; you're just seeing the big lag time to publication. Pubcrawler found the abstract for me, but no, it's not from a major medical journal by any stretch. The data may eventually find it's way into an article in a major medical journal in the future, though. I agree, I don't recall any disclosure of this stuff anywhere else, including corporate presentations, so I assume it's recent as well, as far as the public is concerned. At least with respect to the MOA as detailed in the abstract. However, it is likely in the stock price. The protocols do exclude pregnant women and those not on birth control if they are sexually active. See: clinicaltrials.gov For example. Note that protocol was posted at least a few weeks ago. Cheers, Tuck, who just became a shareholder again today.